X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

    Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

    Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021

    GSK and CureVac to develop next generation mRNA COVID-19 vaccines

    Oxford leads first trial investigating dosing with alternating vaccines

    Oxford leads first trial investigating dosing with alternating vaccines

    Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines

    Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines

    Merck, Pfizer get EU nod for Bavencio as bladder cancer maintenance

    Merck, Pfizer get EU nod for Bavencio as bladder cancer maintenance

    Boehringer Ingelheim and Enara Bio Partner on Cancer Immunotherapies

    Boehringer Ingelheim and Enara Bio Partner on Cancer Immunotherapies

    Pfizer’s new partnership focuses on digitising clinical trials

    Pfizer Invests $120 Million in Biotechnology Innovation

    DCGI nod to Serum-Oxford covid-19 vaccine for phase 2, 3 clinical trials in India

    Baxter Biopharma Announces Sterile Manufacturing Agreement for Novavax COVID-19 Vaccine

    Pfizer and BioNTech Announce Agreement with the UK 30 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2

    Baxter Biopharma Announces Sterile Manufacturing Agreement for Novavax COVID-19 Vaccine

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

    Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

    Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021

    GSK and CureVac to develop next generation mRNA COVID-19 vaccines

    Oxford leads first trial investigating dosing with alternating vaccines

    Oxford leads first trial investigating dosing with alternating vaccines

    Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines

    Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines

    Merck, Pfizer get EU nod for Bavencio as bladder cancer maintenance

    Merck, Pfizer get EU nod for Bavencio as bladder cancer maintenance

    Boehringer Ingelheim and Enara Bio Partner on Cancer Immunotherapies

    Boehringer Ingelheim and Enara Bio Partner on Cancer Immunotherapies

    Pfizer’s new partnership focuses on digitising clinical trials

    Pfizer Invests $120 Million in Biotechnology Innovation

    DCGI nod to Serum-Oxford covid-19 vaccine for phase 2, 3 clinical trials in India

    Baxter Biopharma Announces Sterile Manufacturing Agreement for Novavax COVID-19 Vaccine

    Pfizer and BioNTech Announce Agreement with the UK 30 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2

    Baxter Biopharma Announces Sterile Manufacturing Agreement for Novavax COVID-19 Vaccine

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines

Content Team by Content Team
28th January 2021
in Drug Development, Featured, Press Statements
Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that it is expanding its pipeline of innovative vaccines with three new development programs based on the clinical success of its infectious disease vaccine portfolio to date. This announcement reflects the Company’s commitment to accelerating its infectious disease portfolio based on Moderna’s experience with its COVID-19 vaccine. The development programs announced today are mRNA vaccine candidates against seasonal flu, HIV and the Nipah virus. Moderna also announced an expansion of its respiratory syncytial virus (RSV) vaccine program into older adults.

“The uniquely challenging year of 2020 for all of society proved to be an extraordinary proof-of-concept period for Moderna,” said Stéphane Bancel, Moderna’s chief executive officer. “Even as we have shown that our mRNA-based vaccine can prevent COVID-19, this has encouraged us to pursue more-ambitious development programs within our prophylactic vaccines modality. Today we are announcing three new vaccine programs addressing seasonal flu, HIV and the Nipah virus, some of which have eluded traditional vaccine efforts, and all of which we believe can be addressed with our mRNA technology. Beyond vaccines, we are extending our mRNA development work to a total of 24 programs across five therapeutic areas.”

Mr. Bancel will present an update on the Company and its pipeline of mRNA development programs on Monday, January 11, 2021 at 4:30 p.m. ET at the 39th Annual J.P. Morgan Healthcare Conference. The presentation will be followed by a question-and-answer session. A live webcast of both the presentation and question and answer session will be available under “Events & Presentations” in the investors section of Moderna’s website at investors.modernatx.com. A replay of the webcast will be archived on Moderna’s website for 30 days following the presentation.

About Moderna
In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the promising-but-still-unproven field of messenger RNA (mRNA), to an enterprise with its first medicine having treated millions of people, a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna’s capabilities have come together to allow the authorized use of one of the earliest and most-effective vaccines against the COVID-19 pandemic.

Moderna’s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Today, 24 development programs are underway across these therapeutic areas, with 13 programs having entered the clinic. Moderna has been named a top biopharmaceutical employer by Science for the past six years.

Previous Post

Partnership to Build Cold Chain Monitoring into Pharma Manufacturing, Packaging, Distribution

Next Post

Oxford leads first trial investigating dosing with alternating vaccines

Related Posts

Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate
Clinical Trials

Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

4th February 2021
Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021
Drug Development

GSK and CureVac to develop next generation mRNA COVID-19 vaccines

4th February 2021
Oxford leads first trial investigating dosing with alternating vaccines
Drug Development

Oxford leads first trial investigating dosing with alternating vaccines

4th February 2021
Bemis Healthcare Packaging introduces Insura seal verification technology
Featured

Partnership to Build Cold Chain Monitoring into Pharma Manufacturing, Packaging, Distribution

28th January 2021
Merck, Pfizer get EU nod for Bavencio as bladder cancer maintenance
Drug Development

Merck, Pfizer get EU nod for Bavencio as bladder cancer maintenance

28th January 2021
Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials
Featured

Lilly, Vir Biotechnology and GSK announce first patient dosed in expanded BLAZE-4 trial evaluating bamlanivimab with VIR-7831 for COVID-19

28th January 2021
Next Post
Oxford leads first trial investigating dosing with alternating vaccines

Oxford leads first trial investigating dosing with alternating vaccines

Latest News

Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate
Clinical Trials

Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

4th February 2021
CSafe Global to present new Parcel and Cell & Gene thermal shipping solutions
News

CSafe Global Continues Expansion Across Asia with Two New Hub Locations in China

4th February 2021
Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021
Drug Development

GSK and CureVac to develop next generation mRNA COVID-19 vaccines

4th February 2021
Oxford leads first trial investigating dosing with alternating vaccines
Drug Development

Oxford leads first trial investigating dosing with alternating vaccines

4th February 2021
Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines
Drug Development

Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines

28th January 2021
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In